A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Relapsing Forms of Multiple Sclerosis (RMS) or Pr

Protocol No

NEURO-BMS-CA061-1006

Staff Member

Ahmed Obeidat

Phase

Summary

This project is being done to see if the investigational therapy called CC-97540 is safe and tolerable to treat multiple sclerosis (MS).

Objective

Dose Escalation Study of CC-97540 in RMS or PM

Study Sites

Froedtert Hospital

Status

OPEN TO ACCRUAL

A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS)